Acrivon Therapeutics, Inc. (ACRV) Tops Q1 EPS by 50c

Acrivon Therapeutics, Inc. (NASDAQ: ACRV) reported Q1 EPS of ($0.51), $0.50 better than the analyst estimate of ($1.01).

For earnings history and earnings-related data on Acrivon Therapeutics, Inc. (ACRV) click here.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• ICICI Securities Resumes Dalmia Bharat Ltd (DALBHARA:IN) at Add (2)
• Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)